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Abstract – We will review the main animal models for the major neuropsychiatric disorders, focusing on schizophrenia, 
Alzheimer’s disease, Parkinson’s disease, depression, anxiety and autism. Although these mental disorders are specifically 
human pathologies and therefore impossible to perfectly replicate in animals, the use of experimental animals is based on 
the physiological and anatomical similarities between humans and animals such as the rat, and mouse, and on the fact that 
99% of human and murine genomes are shared. Pathological conditions in animals can be assessed by manipulating the 
metabolism of neurotransmitters, through various behavioral tests, and by determining biochemical parameters that can 
serve as important markers of disorders.
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SChIzOPhRENIA
Although the complex pathology of schizophrenia 
cannot  be  replicated  completely  in  animals,  stud-
ies  conducted  on  postmortem  collected  tissues  of 
schizophrenic patients and brain imaging techniques 
revealed  neuroanatomical  and  neurophysiological 
changes that could be used to generate animal mod-
els of schizophrenia, such as reductions of the cortical 
volume, in particular the frontal cortex, hippocam-
pus and temporal lobes (Kircher, 2006). An impor-
tant aspect in this field would also be the fact that 
these reductions can appear both before the onset of 
the disease and progressively afterwards, thus indi-
cating a neurodegenerative nature (Webster, 2005).
Regarding changes in neurotransmitter systems 
which  could  be  used  to  generate  possible  animal 
models of schizophrenia, it has been found that at the 
level of the central nervous system of schizophren-
ics, there is an increased quantity of dopamine and 
a large number of dopamine receptors, in particular 
D2. The administration of neuroleptics or antipsy-
chotics that have an antagonistic action on dopamine 
D2 receptors exerts a favorable effect, while amphet-
amines, which are dopamine agonists, increase the 
schizophrenic symptoms (Jerlhag, 2008).
Moreover, this disorder is characterized by a hy-
peractivity of the dopaminergic system, mainly the 
mesolimbic dopaminergic pathway that connects the 
midbrain ventral tegmental area to the nucleus ac-
cumbens (Marcotte et al., 2011). Given the relevance 
of this area to the positive symptoms of the disor-
der (Pakkenberg, 1990), our research group has car-
ried out experiments regarding the significance of 
lesioning the nucleus accumbens in specific behav-
ioral tests, including changes that this injury exerts 
on the main markers of the oxidative stress (Lefter 
et al., 2013). Given the roles that smoking and nico-1106 RADU LEFTER ET AL.
tine have in schizophrenia (smoking is traditionally 
considered self-medication in schizophrenics), the 
effects of the administration of nicotine to animal 
models were examined (Ciobica et al., 2012).
Another region of potential significance in ani-
mal models of schizophrenia is the prefrontal cortex 
and in particular its dorsolateral side. In humans, 
injury  to  this  area  produces  serious  deficiencies 
in  attention  and  cognitive  processes.  however,  in 
schizophrenics this area does not display a specific 
pathology, although some authors speak of a degree 
of local atrophy and a reduction in the number of 
neurons (Webster, 2005). It is considered that this 
nervous structure may explain why the first schizo-
phrenia symptoms occur after adolescence. The my-
elinization of this area is not complete until the age 
of 20, and experimental injury of this area in young 
monkeys does not generate immediate cognitive im-
pairments, instead it decreases the ability to perform 
some cognitive tests (Kerwin, 1997).
Another important aspect that may be of rele-
vance in generating animal models of schizophrenia 
is presynaptic glutamate receptor deficiency, which 
seems to be one of the major causes of schizophre-
nia, as the administration of metabotropic receptor 
mGlu2/3 agonists was reported to be effective in the 
treatment  of  some  schizophrenic  symptoms  (Patil 
et al., 2007). Similar symptoms of schizophrenia are 
also produced by the administration of glutamate an-
tagonists for NMDA receptors, such as ketamine and 
phencyclidine, which are important indicators of the 
important role of the glutamatergic system function-
ing in schizophrenia (Reynolds et al., 2005). Related 
to  glutamatergic  transmission,  another  model  of 
schizophrenia in rats proposes the administration of 
methionine a glutamate inhibitor, as a blocker for this 
neurotransmitter. While the administration of phen-
cyclidine and ketamine in rat models was reported to 
lead to an increased release of dopamine, the admin-
istration of antipsychotics attenuates this effect (Jent-
sch and Roth, 1999). Moreover, the administration 
of agonists for the clozapine group II metabotropic 
receptors can block the effects of phencyclidine and 
ketamine (Deutsch et al., 2002).
Regarding the areas that are relevant in mimick-
ing schizophrenic neuropathology, the glutamater-
gic  receptors  are  densely  distributed,  especially  in 
the hippocampus and limbic system, areas that are 
known to suffer important anatomical and function-
al alterations in schizophrenia (Webster, 2005).
In postmortem tissue samples of patients with 
schizophrenia,  decreases  in  the  concentrations  of 
aspartic and glutamic acids in the frontal cortex, as 
well as alterations in the activity of the enzyme that 
converts  N-acetylaspartylglutamate  (NAAG)  have 
been observed (Tsai et al., 1995).
In addition, serotonin (5-hT) is considered to be 
involved in the regulation of the dopaminergic sys-
tem in the prefrontal cortex, striatum (including the 
nucleus accumbens) and mesencephalic ventral teg-
mental area, thereby influencing schizophrenic pa-
thology. This was also shown in postmortem studies 
that indicated an increased density of 5-hT1 recep-
tors in the prefrontal cortex. 5-hT1 agonists produce 
an increase in dopamine release from the rat prefron-
tal cortex, which could favor the negative symptoms 
of schizophrenia (Bantick et al., 2001).
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form 
of  dementia  and  at  present,  the  most  widespread 
neurodegenerative disorder (Webster, 2005). AD has 
a complex pathology, reflecting a variety of connect-
ed cellular and molecular abnormalities.
The  “cholinergic  theory”  addresses  both  aging 
and AD. It states that cognitive disturbances in are 
due to a deficit in acetylcholine, which has an estab-
lished role in learning and memory processes. These 
issues are particularly important for the generation 
of animal models mainly based on the administra-
tion of specific cholinergic antagonists (e.g. scopo-
lamine, a muscarinic blocker) (Ciobica et al., 2009).
It has been observed that with aging, as well as 
in the case of some types of dementia, the synthe-
sis of acetylcholine decreases by 45-65%, as enzymes ASPECTS OF ANIMAL MODELS FOR MAJOR NEUROPSYChIATRIC DISORDERS 1107
involved  in  its  metabolism  degrade,  undergoing 
isomerization  processes  that  alter  their  properties 
and performance. Thus, AD was considered the pro-
totype of cholinergic neurotransmission impairment 
(Webster, 2005).
Additionally, the cholinergic hypothesis for the 
etiology of AD grants a primary role to the choliner-
gic neurons connected with muscarinic receptors sit-
uated in the cerebral cortex that degenerate preferen-
tially in this form of presenile dementia. The decline 
in acetylcholine content is linked to the depletion of 
choline acetyltransferase, the enzyme responsible for 
acetylcholine synthesis, whose activity is reduced by 
90% in the brains of patients with Alzheimer’s dis-
ease. This reduction also occurs in the same brain 
regions that contain large amounts of amyloid β pro-
tein (Artenie et al., 2010).
There  is  substantial  evidence  that  muscarinic 
blocking by scopolamine disrupts memory in young 
volunteers in a reversible manner that was qualita-
tively similar to that occurring naturally in demented 
subjects (Liem-Moolenaar et al., 2011). Scopolamine-
treated normal young human subjects exhibit mem-
ory  dysfunctions  analogous  to  those  observed  in 
demented patients. These dysfunctions are reversible 
by physostigmine, but not by d-amphetamine, which 
suggests that the memory impairment is specifically 
related to reduced cholinergic transmission caused 
by scopolamine. In this way, scopolamine-induced 
amnesia has been proposed as a fundamental model 
for dementia where reduced cholinergic function is 
the suspected cause, as well as to potentially test anti-
dementia drugs by their ability to protect against the 
cognitive impairment induced by cholinergic dys-
functions (Lee et al., 2012).
In both cases of these anticholinergic-induced 
animal  models  of  dementia  those  based  on  the 
knock-out  of  specific  genes  implicated  in  demen-
tia, the detection and confirmation of the cognitive 
deficiencies in animal models of AD is performed 
through specific behavioral tests that assess changes 
in memory and learning performance, such as the Y-
maze task (Ciobica et al., 2012), radial 8 arm maze 
task (Gurzu et al., 2008), passive (Bild et al., 2013) or 
active avoidance (hritcu et al., 2009).
Parkinson’s disease
Parkinson’s  disease  (PD)  is  the  second  neurode-
generative disorder after Alzheimer’s disease in the 
number  of  affected  patients  (Webster,  2005).  Our 
laboratory has utilized an animal model of PD in rats 
(hefco et al., 2003) using stereotaxic neurosurgical 
techniques in order to perform selective dopaminer-
gic damage to the substantia nigra and ventral area 
tegmental area (part of the mesotelencephalic cen-
tral dopaminergic system) (hritcu et al., 2008). This 
is done by the administration of 6-OhDA, a toxin 
specific for catecholaminergic neurons (Ciobica et 
al., 2009).
These stereotaxic techniques require special at-
lases that describe in detail the specific areas at the 
central level of the studied animal, such as the atlas 
of Paxinos and Watson (2006). According to the atlas 
for the substantia nigra, with the bregma point (situ-
ated at the intersection of the coronal suture with the 
sagittal suture) as the point of reference, the follow-
ing stereotaxic coordinates were established: 5.5 mm 
posterior to the bregma, 2 mm lateral to the sagittal 
suture and 7.4 mm ventral to the surface of the cor-
tex (Fig. 1).
In most of our experiments, 8 μg of 6-OhDA 
dissolved in 4 μl physiological saline containing 0.1% 
ascorbic  acid,  was  administrated  with  a hamilton 
syringe over 4.50 min., and the syringe was left in 
place for 5 min after injection before being slowly re-
moved (Fig. 1). The catecholaminergic terminations 
were initially protected through the administration 
of desipramine.
 Despite the fact that PD has traditionally been 
considered a motor disorder, there has been much 
recent  interest  in  the  nature  of  cognitive  impair-
ment  in  PD,  ranging  from  minor  disturbances  in 
memory  to  various  intellectual  functions  and  de-
mentia (Kramberger et al., 2010). Additionally, there 
is a growing concern regarding the role of oxidative 1108 RADU LEFTER ET AL.
Fig. 1. Different steps in obtaining a rat model of Parkinson’s 
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stress in the pathogenesis of PD (Abeliovich, 2010), 
and it is now generally accepted that oxidative pathol-
ogy contributes to the cascade leading to dopamine 
cell degeneration in PD (Jenner, 2003), although the 
exact mechanisms are not yet fully understood. For 
this reason, our research group has examined the 
relevance of several possible treatments (pergolide/
nicotine) in a rat model of PD, to learning and mem-
ory processes, using several behavioral tasks such as 
Y-maze, shuttle-box tasks or radial 8-arm maze, in-
cluding antioxidant enzyme activities from both the 
temporal and frontal lobe tissue (Ciobica et al., 2010, 
2011), and oxidative stress in different neuropsychi-
atric disorders (Bild et al., 2013; (Padurariu et al., 
2013; Stefanescu et al., 2012).
Anxiety
One of the classical approaches to the generation of 
animal models for the study of anxiety is based on 
the assumption that depression and anxiety are at-
tenuated by agents that alter noradrenergic transmis-
sion, as these disorders are considered a neurodegen-
eration of the wake reaction (Webster, 2005). Since 
noradrenalin determines the emotional impact of a 
given stimulus, depression can be explained by in-
adequate noradrenergic transmission, which would 
mean that moderate noradrenergic activity causes at-
tention, which is vital for proper cognitive function, 
and excessive noradrenergic activation climaxes into 
anxiety and agitation. In fact, any test that explores the 
memory and learning processes (such as those men-
tioned above) is affected by an animal’s anxiety state, 
as the substances that modify this state are implicitly 
modifying the cognitive response. Thus, the link be-
tween anxiety and the formation of a new memory 
engram is based on the animal’s tendency to get to 
know and explore new stimuli, against its natural ten-
dency to avoid what is new and unknown, this con-
flict generating the anxiety condition (Bild, 2013).
The associative learning processes are linked to 
the same issues, the subject avoiding a stimulus that 
generated on another occasion an unpleasant sensa-
tion. These states are in general treated with benzo-
diazepines (diazepam being the classic example) that 
have specific binding sites in the brain (Espey et al., 
2002). Benzodiazepines alleviate the noradrenaline 
turnover at the central level, thereby reducing the 
impact of certain stimuli, which would cause an in-
crease in the release of neurotransmitters (e.g. appli-
cation of an electrical shock in lower limb area). They 
would also be involved in decreasing the discharge 
rate of neurons in the locus coeruleus (Vermetten et 
al., 2002).
Other noradrenergic-mediated central areas are also 
relevant in this matter. Thus, the exposure of an ani-
mal to a new aversive stimulus, for example a long 
exposure to intense light, increases the concentration 
of extracellular norepinephrine in the frontal cortex, 
as well as in the hypothalamus. If a sound stimulus 
is activated each time an animal is moved into an in-
tensely illuminated room, after a number of repeti-
tions the animal will make an association between the 
events, which will change the degree of noradrener-
gic involvement in this process, the audible stimulus 
increasing the concentration of noradrenaline in the 
frontal cortex, but not in the hippocampus (Webster, 
2005). Thus, the noradrenergic innervation of these 
two  nervous  areas  is  of  particular  importance  for 
anxiety, considering the different roles in the genera-
tion of the conditioned response that occur because 
of exposure to various aversive stimuli. The prefron-
tal cortex would most likely generate responses to 
conditioned  stimuli  that  are  already  known  to  be 
anxiogenic, while both areas appear to be involved in 
generating responses to unconditioned stimuli (Mc-
Quade et al., 2000). These two regions, along with the 
amygdala, septo-hippocampal system, hypothalamus 
and grey periaqueductal substance, are considered to 
form the so-called neuronal defense system, which is 
particularly important in the conditioning processes 
to various noxious stimuli (Bild et al., 2013).
Besides  neurosurgical  and  pharmacological 
modulation of anatomical areas that serve to gener-
ate animal models of anxiety, there are also several 
specific behavioral tests that help our understand-
ing of disease pathology. The elevated plus maze 
(EPM) is a well-known behavioral test for studying 
the anxiety state (Espey et al., 2002). In short, the 1110 RADU LEFTER ET AL.
elevated plus maze consists of four arms, elevated 
off   the ground (Fig. 2). Two arms are enclosed by 
high walls and the other two arms are exposed. Rats 
are placed at the juncture of the open and closed 
arms and the amount of time spent in the open 
arms is recorded during a 5-min test (along with 
some  other  specifi  c  anxiety-related  parameters). 
Th   e time spent in the open arms is considered an 
index of anxiety.
Depression
Regarding  depression,  from  a  neurophysiological 
point of view the generation of some animal models 
of depression could be focused on the main neuro-
transmitters involved in its neuropathology, consid-
ered to be serotonin, noradrenaline and dopamine 
(Webster, 2005).
Th   e  serotonin  hypothesis  of  depression  origi-
nates in the involvement of serotonin in the regula-
tion of the majority of functions aff  ected by depres-
sion, such as motor activity, sexual behavior, sleep, 
appetite,  food  intake,  anxiety,  aggressiveness  and 
impulsivity. Serotonin defi  ciency is thus considered 
an immediate cause of depression, and several stud-
ies have indicated decreasing plasma levels of tryp-
tophan, the precursor of serotonin, in depressed pa-
tients (Almeida-Montes et al., 2000).
Th   e study of serotonin metabolites, and in par-
ticular 5-hydroxyindoleacetic acid (5-hIAA) in the 
cerebrospinal fl  uid of depressed patients, shows a de-
crease in its level, although this was connected with 
suicidal behavior and impulsiveness rather than with 
depression per se (Sullivan et al., 2006).
Inadequate  noradrenergic  transmission  also 
seems to be involved in the mechanism of depres-
sion, given that the noradrenergic system infl  uences 
the emotional impact of a given stimulus and par-
ticipates  alongside  the  dopaminergic  mesolimbic 
system in motivation and pleasure. In this way, the 
administration of reserpine generates serious behav-
ioral changes in the rat, characterized by the lack of 
reaction  to  almost  any  stimulus  (a  feasible  model 
of depression may be thus obtained) and the motor 
idleness. Th   is ‘reserpinic syndrome’ is attributed to 
the depletion of vesicular deposits of noradrenaline. 
When these reserpinic animal models were injected 
with iproniazid, which is an irreversible inhibitor of 
monoamine oxidases (MAO), the above-mentioned 
eff  ects disappeared, the animals exhibiting even ex-
aggerated mobility, which demonstrates the involve-
ment of norepinephrine in the pathology of depres-
sion (Webster, 2005).
One the best-known processes in this respect is 
learned  helplessness,  which  comprises  behavioral 
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changes in animals that are unable to escape from a 
harmful stimulus (for example, an animal in a cage 
from which it cannot escape and where is exposed to 
repeated electrical shocks at short intervals). After a 
period of time in which the animal attempts to avoid 
the stimulus, its state changes to a general disinterest 
and passivity towards most stimuli, refusing to seek 
an escape even when this becomes once more pos-
sible. These animals were found to exhibit a marked 
reduction in the turnover of central norepinephrine, 
in particular at the level of the cortex, hypothalamus 
and  hippocampus,  areas  of  critical  importance  in 
learning and memory processes. Moreover, the ad-
ministration of substances involved in the noradren-
ergic depletion (such as reserpine) further aggravates 
this condition.
It seems that this process could be explained by 
the depletion of the available stock of noradrena-
line in these areas as a result of repeated exposure to 
harmful stimuli. It should however be stated that in 
this process other neurotransmitter systems such as 
the GABA-ergic, cholinergic or the opioid systems, 
are also involved, which interact with the noradren-
ergic neurotransmission that seems to hold the cru-
cial role. A similar phenomenon is observed when a 
rat is placed in a pool from which it cannot escape 
and in which there is no platform (Anisman, 1997).
It  is  generally  thought  that  norepinephrine 
stimulates  behavioral  activity  and  nervous  activa-
tion, with a beneficial effect on memory and learning 
processes. Thus, the various promoters of the central 
nervous system, such as amphetamines, increase the 
release of noradrenaline, resulting in the intensifica-
tion of various behavioral processes and of amplitude 
waves on an EEG, while reserpine, which reduces the 
stocking and release of norepinephrine, causes a gen-
eral psychomotor retardation. It was also noted that 
the discharge rate of the neurons that project from 
the locus coeruleus gradually increases depending 
on the complexity of the behavioral act that has been 
performed. In the same way, stimulation of the lo-
cus coeruleus causes the desynchronization of EEG 
rhythms and increases the neuronal activation sta-
tus, while neurotoxic lesioning of its local neurons 
synchronizes the EEG rhythms and reduces the pe-
riod of REM sleep.
A standard test used to assess the properties of 
possible antidepressant medication in the rat is rep-
resented by the forced-swimming test (Foyet et al., 
2011). On the first day of this test that is relevant in 
generating animal models of depression, the rats are 
individually placed into cylindrical recipients (diam-
eter 30 cm, height 59 cm) containing 25 cm of water. 
The animals are left to swim for 15 min before being 
removed, dried and returned to their cages (pretest 
session). The procedure is repeated 24 h later, in a 
6-min swim session (test session). During the test 
session, the following behavioral responses are re-
corded: immobility (time spent floating with mini-
mal movements to keep the head above the water) 
and swimming (time spent actively swimming). In-
creased percentages of immobility time will suggest 
more depression-like manifestations.
Autism
Although it is not possible to reproduce all autis-
tic symptoms in animals such as the deficiencies of 
language or intuitive ability, most animal models of 
autism developed so far are able to shape a series of 
typical symptoms through certain tasks that assess 
sociability, vocalization or the change of routine.
It has been found that all teratogenic agents that 
can induce this complex disorder act during the first 
eight weeks after conception (Crawley, 2012). While 
this is a very important aspect in the generation of 
potential animal models of autism, it also represents 
evidence that autism arises very early in develop-
ment of an individual.
Abnormalities  of  the  serotoninergic  system 
are largely indicated as the main mechanism in the 
pathogenesis  of  the  autistic  spectrum.  Moreover, 
most of the brain regions considered responsible for 
autism are densely innervated by projections of se-
rotoninergic neurons (cerebral cortex, with the pre-
frontal lobe and superior temporal gyrus, the brain-
stem with the dorsal raphe nucleus, upper and lower 1112 RADU LEFTER ET AL.
olivary nuclei, the nucleus of the facial nerve or the 
limbic system) (Kinast et al., 2013).
To date there are relatively few models of autism 
of mice and rats mentioned in the literature. Accord-
ing to Crawley, there are several diff  erent approaches 
regarding the methods for designing autistic animal 
models. On the one hand, there are the genetic muta-
tions either of genes responsible for neurotransmis-
sion, or regulation of social behavior (e.g. autistic 
models of mice obtained by mutations of genes for 
oxytocin or vasopressin, (Crawley, 2004, 2012). On 
the other hand, some models can be obtained by in-
ducing abnormalities in neurotransmitters or certain 
brain areas that are aff  ected in autistic patients. By 
this approach and considering the reported autistic 
eff  ects of early fetal exposure to teratogens, Patricia 
Rodier developed a model of autism in rodents by 
prenatal  exposure  of  the  animals  to  valproic  acid 
(VPA). Th   is method consists of injecting pregnant 
females during neural tube enclosure stage of em-
bryonic development with VPA (Rodier et al., 1996; 
Crawley, 2004).
Valproic acid is a carboxylic acid and a valeric 
acid analog, with antidepressant and anticonvulsive 
actions.  It  is  used  for  treating  epilepsy  and  vari-
ous  bipolar  disorders  or  depression.  It  stimulates 
the GABA neurotransmission by inhibiting GABA 
transaminase.
Following prenatal exposure to VPA, more brain 
abnormalities similar to the phenomena in human 
cases of autism were recorded, such as a decreased 
number  of  Purkinje  cells,  neuronal  degeneration, 
altered distribution of 5-hT neurons in the dorsal 
raphe nucleus, cell losses in the middle and lower 
layers of the prefrontal cortex and in the lower layers 
of the somatosensory cortex. Although behavioral 
testing is not well established and there is no defi  ned 
set of tasks relevant to autistic symptoms, these were 
partially described in previous literature (Crawley et 
al., 2004). Th   us, autistic symptomatology should be 
assessed in relation to social interactions, sociability, 
communication and repetitive behavior. 
For assessing the sociability parameter and espe-
cially for studying an abnormally low level of sociabil-
ity in very social species such as rat or mouse, Craw-
ley et al. (2004) suggests using a special tricameral 
device: the animal is placed in the central compart-
ment (1), so that it is given the choice of whether to 
interact (2) or not (3) with a unknown animal placed 
into one of the two lateral compartments (Fig. 3).
Fig. 3. Social interaction paradigm for the study of autism using a rat ASPECTS OF ANIMAL MODELS FOR MAJOR NEUROPSYChIATRIC DISORDERS 1113
Repetitive  behavior  is  described  as  rigidity  to 
change  an  activity  that  has  become  routine.  As  a 
common trait in autism, rodents can be trained in 
repetitive behavior until the adoption of some rou-
tines and then tested when changing the condition-
ing stimulus. As a working method, the use of the 
T-maze  task  (alternation  task)  was  proposed.  Th   e 
animal subjects are trained to choose only one of the 
two opposite arms of the maze, where they would 
fi  nd a food reward. Th   e development of routine is 
accomplished when the tested animal makes at least 
8 out of 10 correct choices for three consecutive days, 
aft  er which the food pellet is moved to the opposite 
arm (Fig. 4).
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